Case Reports in Endocrinology
Volume 2020 (2020), Article ID 2128093, 8 pages
https://doi.org/10.1155/2020/2128093

Case Report

An Unusual Simultaneous Existence of Parathyroid Carcinoma and Papillary Thyroid Carcinoma: Case Report and Review of Literature

César Ernesto Lam-Chung,¹ Diana Lizbeth Rodríguez-Orihuela,² Jazmín De Anda González,² and Armando Gamboa-Domínguez²

¹Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, México City 14000, Mexico
²Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, México City 14000, Mexico

Correspondence should be addressed to Armando Gamboa-Domínguez; agamboad@gmail.com

Received 4 January 2020; Accepted 20 February 2020; Published 31 March 2020

Academic Editor: J. Paul Frindik

Copyright © 2020 César Ernesto Lam-Chung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Synchronous parathyroid and papillary thyroid carcinoma are extremely rare. To our knowledge, only 15 cases have been reported in the last four decades. We describe a 50-year-old female without significant past medical or family history and no previous trauma presented with left heel pain that prompted her to seek medical attention. Physical examination was notable for a painless nodule at the left thyroid lobe. Laboratory evaluation showed a serum calcium level of 14.3 mg/dL (8.6–10.3 mg/dL) and intact parathyroid hormone level of 1160 pg/mL (12–88 pg/mL). 99Tc-sestamibi dual-phase with single-photon emission computed tomography fused images showed increased uptake at the left-sided inferior parathyroid gland. Neck ultrasound showed a 1.4 cm heterogeneous nodule in the middle-third of the left thyroid gland and a solitary 1.9 cm vascularized and hypoechoic oval nodule that was considered likely to represent a parathyroid adenoma. Due to its clinical context (severe hypercalcemia and very high levels of PTH), parathyroid carcinoma (PC) was suspected although imaging studies were not characteristic. The patient underwent en bloc resection of the parathyroid mass and left thyroid lobe and central neck compartment dissection. Pathology analysis revealed classical papillary thyroid carcinoma of classical subtype and parathyroid carcinoma. Immunohistochemical staining was positive for cyclidin D1 and negative for parafibromin. High clinical suspicion is required for parathyroid carcinoma diagnosis in the presence of very high level of parathyroid hormone, marked hypercalcemia, and the existence of any thyroid nodule should be approached and the coexistence of other carcinomas should be considered.

1. Introduction

Less than 1% of all cancers and primary hyperparathyroidism (PHPT) can be attributed to parathyroid carcinoma (PC) [1, 2]. The vast majority of cases are sporadic, whereas the rest occur in the context of genetic syndromes such as multiple endocrine neoplasia type 1 (MEN1) or hyperparathyroidism-jaw tumor syndrome (HPT-JT) [3, 4]. It has equal frequency in both genders and usually occurs during the fifth decade of life [1, 2]. Very high serum levels of intact parathyroid hormone (iPTH) and severe hypercalcemia are the main biochemical findings and clinical manifestations are due to its excessive secretion [5, 6]. It is usually diagnosed postoperatively with histology assessment given its absence of specific clinical and biochemical features [2].

Papillary thyroid cancers (PTCs) account the majority (80–85%) of thyroid cancer cases, specifically papillary thyroid microcarcinomas (PTMs) [7–9]. Radiation exposure and genetics are the known risk factors for PTCs. However, only 5% of PTC cases account for familial PTC [10]. It occurs predominantly in female, and the median age at presentation is 50 years [11]. An asymptomatic thyroid mass is usually the main clinical finding, and it can be accompanied with or without cervical lymph node enlargement. However, vocal cord paralysis and tracheal compression can be present in about 20% of PTC cases, and it is manifested as hoarseness and dysphagia [12]. Biochemical tests are of limited usefulness because most patients have normal thyroid function [13].

The coexistence of thyroid and parathyroid carcinoma is extremely infrequent. Here, we describe a patient with this unusual presentation.

2. Case Presentation

A 50-year-old female without significant past medical or family history and no previous trauma presented with pain on her left heel that prompted her to seek medical attention. Initial evaluation was notable for serum concentration of calcium 14.3 mg/dL (normal range 8.6–10.3 mg/dL), alkaline phosphatase of 339.4 U/L (normal range 34–104 U/L), creatinine of 1.8 mg/dL (normal range 0.3–0.7 mg/dL), and iPTH level of 1160 pg/mL (normal range 12–88 pg/mL). Biochemical data of the patient are summarized in Table 1. Because of the concern for chronic kidney disease, a renal ultrasound was performed and showed both kidney medullary nephrocalcinosis and thinning of the renal parenchyma. Bone densitometry revealed osteoporosis at the anteroposterior spine (T score −2.7) and femoral neck (T score −2.9) and osteopenia at the total hip (T score −2.3). A presumptive diagnosis of parathyroid carcinoma (PC) was made and referred to endocrinology department for further evaluation. Physical examination revealed a hardened and painless nodule at the left thyroid lobe without vocal cord paralysis. Thyroid function test values were within the reference ranges.

Table 1: Laboratory at admission and at two months postoperative.

Laboratory values (normal range)
At admission
At two months postoperatively

Calcemia (8.6–10.3 mg/dL)
14.3
9.5

Ionized calcemia (4.36–5.2 mg/dL)
7.06
4.83

Magnesium (1.9–2.7 mg/dL)
2.1
1.94

Creatinine (0.3–0.7 mg/dL)
2
1.77

Albumin (3.5–5.7 g/dL)
3.68
3.24

Alkaline phosphatase (34–104 U/L)
381
399

PTH (12–88 pg/mL)
1160
7.4

Phosphatemia (2.5–5 mg/dL)
2.73
3.28

25(OH) vitamin D (30–100 ng/mL)
10.1
43

FT4 (0.63–1.34 ng/dL)
0.72
0.97

T3T (0.64–1.81 ng/mL)
1.07
0.79

TSH (0.3–5 mIU/L)
1.8
4.14

A 99mTc-sestamibi dual-phase fusion imaging with single-photon emission computed tomography/computed tomography (SPECT/CT) was performed, and a possible left-sided inferior parathyroid was identified (Figure 1(a)). Neck ultrasonography showed a 1.4 cm heterogeneous nodule and central vascularity in the middle-third of the left thyroid gland (Figures 2(a) and 2(b)). At the same area depicted by SPECT/CT, a 1.9 cm vascularized and hypoechoic oval nodule was present and considered likely to represent a parathyroid adenoma (Figure 1(b)). Due to its clinical context (severe hypercalcemia and very high levels of PTH), PC was suspected although imaging studies were not characteristic. At surgical intervention, a normal-appearing inferior parathyroid gland was identified and preserved in situ. An en bloc resection of the parathyroid mass and left thyroid lobe and central lymph node compartment dissection was performed. On the fourth postoperative day, the iPTH value was 84.6 pg/mL.

(a)

(b)

(c)

(d)

Figure 1: (a, b) 99mTc-sestamibi dual-phase with single-photon emission computed tomography/computed tomography fused images, showing uptake within middle to inferior left lobe of the thyroid. (b, c) Ultrasonograms revealing an oval-shaped hypoechoic solid nodule (1.40 × 1.39 × 1.92 cm) at the same area.

(a)

(b)

Figure 2: (a, b) Ultrasonograms (transverse and sagittal views), demonstrating a fairly oval-shaped solid isoechoic nodule with mixed solid and cystic components (1.38 × 1.14 × 1.36 cm) in the middle portion of the left thyroid lobe.

Gross examination of the surgical specimen revealed a 4.8 × 2.6 × 2.3 cm left thyroid lobe and a 2.4 × 1.8 × 1.4 cm left superior parathyroid gland. Histological examination revealed a 1.3 × 1.2 cm mass at the left thyroid lobe consistent of PTC of classical subtype (Figure 3) and PC, 2.5 cm in widest tumor dimension, with capsular and vascular space invasion (Figure 4). Immunohistochemical staining was positive for cyclidin D1 and negative for parafibromin. Ki-67 index was 2%. Six examined lymph nodes from central compartment were negative for metastasis. Her thyroid carcinoma was staged pT1bN0M0 (TNM AJCC 2018).

(a)

(b)

Figure 3: (a) Histologic appearance of the 1.3 cm papillary carcinoma in the left thyroid lobe, demonstrating a cystic neoplasia with a papillary pattern in transition with residual thyroid normal tissue (hematoxylin-eosin stain original magnification ×4). (b) Histopathological section showing typical features of papillary carcinoma: fibrovascular stalk covered with follicular cells depicting eosinophilic cytoplasm follicular cells and oval nuclei () with pseudoinclusions (blue arrow) (hematoxylin-eosin stain original magnification ×40).

Figure 4: (a) Histology appearance of parathyroid carcinoma in transition with papillary thyroid carcinoma removed from the left thyroid lobe. The neoplastic cells are represented by the monomorphic cellular proliferation with discrete atypia and mitosis (hematoxylin-eosin stain original magnification ×4). (b) Histopathologic section demonstrating capsular invasion and (c) vascular invasion (hematoxylin-eosin stain original magnification ×10).

On the sixth postoperative day, the patient presented hypocalcemic symptoms (calcium 6.9 mg/dL) consistent with hungry bone syndrome. She received intravenous and oral calcium and vitamin D supplementation. Subsequently, she was discharged with oral calcium treatment and remained well, with the latest serum calcium level being 8.6 mg/dL (6 weeks postoperatively).

3. Discussion

The simultaneous presence of thyroid and parathyroid carcinoma is extremely rare with only 15 documented cases [14–30] in the last 41 years, and no correlation, up to date, has been discovered between these entities [31]. Comparison of the previous cases and ours are described in Table 1. The average age was 52 years (range 21–79), and the vast majority were female (80%). According to Surveillance, Epidemiology, and End Results (SEER) database, PTCs usually occur during the fourth and fifth decades of life and have a 2.5 : 1 female-to-male ratio [32], while the reported mean age for PC presentation was 44 to 45 years with an even distribution between genders [33–35]. As a result, the coexistence of thyroid and parathyroid carcinoma may have an impact on the gender distribution and age presentation. Notably, the youngest patient reported had Hürthle cell thyroid carcinoma and PC [21]. Hürthle cell carcinoma is associated with poorer prognosis and higher recurrence rate in local lymph nodes [36, 37].

Almost all patients had functional PC (including our patient) as outlined in Table 2. Nonfunctional PC is much more infrequent than functional PC, and it has a decreased survival due to its absence of symptoms and perhaps to its aggressive biology [16, 39]. To our knowledge, only one case of nonfunctional PC occurring with PTM was reported [40]. Interestingly, all cases with reported PC localization including the one here reported had a preponderance for the left lower side.

Table 2: Clinical and biochemical features of 15 patients with coexistence of parathyroid and thyroid carcinoma.

Reference
Age
Gender
Calcium (mg/dL)
PTH (pg/mL)
Parathyroid gland size (cm)
Carcinoma location
Thyroid carcinoma
Associated parathyroid disease
Surgical treatment
Outcome

Kurita et al. [38]
68
F
12.2
6300
4.2 × 3.2 × 2.4
Left lower
Papillary
None
En bloc resection
Postoperative normocalcemia

Christmas et al. [26]
62
F
Hypercalcemia
Unknown
Unknown
Unknown
Follicular
None
Unknown
Died from metastatic parathyroid carcinoma

Savli et al. [22]
47
F
Normal
Normal
Normal
Unknown
Papillary
Hyperplasia
Total thyroidectomy parathyroidectomy (excision of 2 hyperplastic glands)
Normocalcemia (1 year)

Bednarek-Tupikowska et al. [27]
42
F
15.4
1655
5 cm in diameter
Left lower
Follicular
None
En bloc resection
Persistent hypercalcemia

Schoretsanitis, 2002 [24]
55
F
14.2
>1000
3 × 3
Left lower
Papillary
None
En bloc resection
Normocalcemia (6 years)

Kern et al. [28]
54
F
Unknown
465
2.5 × 1.8 × 1.6
Right lower
Papillary and follicular
None
Right parathyroidectomy; total thyroidectomy with local lymph node resection; corticectomy in the right superior frontal gyrus
Died from intracranial metastatic parathyroid carcinoma

Lin et al. [25]
38
M
16.5
351
4 × 3 × 3
Left lower
Papillary
Two enlarged parathyroid glands on contralateral side
Total thyroidectomy and left parathyroidectomy
Normocalcemia (6 years)

Goldfarb et al. [16]
58
M
14.4
2023
3.4 × 3.3 × 2.2
Left lower
Papillary
Contralateral parathyroid adenoma
En bloc resection
Persistent hypercalcemia after resection of parathyroid carcinoma; normocalcemia after excision of contralateral parathyroid adenoma (1 year)

Marcy et al. [17]
42
F
14.1
383
1.3
Right lower
Papillary
None
Total thyroidectomy, right parathyroidectomy, and central and lateral neck dissection
Normocalcemia (14 months)

Chaychi et al. [18]
79
F
10.4
89
1.1 × 1.2 × 4.8
Left superior
Papillary
None
Total thyroidectomy and left parathyroidectomy
Normocalcemia (6 months)

Amoodi et al. [19]
48
F
Unknown
186
>5
Left lower
Papillary
None
En bloc resection
Persistent hypercalcemia after resection of parathyroid carcinoma; hypoparathyroidism after completion of parathyroidectomy

Zakerkish et al. [21]
21
M
13
1311
Unknown
Unknown
Hürthle
None
Total thyroidectomy and parathyroidectomy
Persistent hypercalcemia and died due to its complications

Song et al. [30]
45
F
17
1455
4.28 × 3.09 × 2.54
Left lower
Papillary
None
Left parathyroidectomy and left thyroid lobectomy plus left neck dissection
Persistent hypercalcemia after left parathyroidectomy; normocalcemia after left thyroid lobectomy plus left neck dissection (6 months)

Baek et al. [23]
68
F
12.8
1247
4.2 × 3.3 × 3.1
Left lower
Papillary
None
Left inferior parathyroidectomy and left thyroid lobectomy
Postoperative normocalcemia

Kuzu et al. [29]
52
F
11.4
208
Unknown
Unknown
Papillary
None
Right parathyroidectomy and right thyroid lobectomy
Postoperative normocalcemia

Our case
50
F
13.9
1160
2.4 × 1.8 × 1.4
Left superior
Papillary
None
Left inferior parathyroidectomy and left thyroid lobectomy
Postoperative normocalcemia

A common but not diagnostic features of PC include trabecular architecture of the parenchymal cells, a thick capsule, fibrous trabeculae traversing the gland, nuclear atypia, and high mitotic rates [41–43]. Criteria for definitive diagnosis of PC consist of capsular and vascular invasion, adjacent tissues invasion, involvement of regional lymph nodes, and distant metastatic lesions. Because cell seeding can occur due to the rupture of capsule in the operative field, locally recurrent disease is not diagnostic. Our patient had a clear capsular and vascular invasion (Figures 2(b) and 2(c)), making the diagnosis of PC unequivocal. It has been reported that extracapsular vascular invasion correlates best with the diagnosis [33].

Risk factors for PC include history of neck irradiation, long-standing secondary hyperparathyroidism (HPT), end-stage renal disease, and hereditary HPT-jaw tumor syndrome. Additionally, mutation of parafibromin (HRPT2, also known as CDC73) and cyclin D1 (CCND1) plays an important role in the molecular pathogenesis of PC [1, 44, 45]. Our patient has no history of neck irradiation and has not underwent genetic testing.

Here, we describe a case of a PTH-secreting PC that had an appearance of parathyroid adenoma in imaging studies. It was suspected due to marked hypercalcemia and a very high iPTH and renal and bone disease. PTC was only diagnosed postoperatively with histological examination.

Radical surgery provides the best possibility of cure. However, more than 50% of the patients have persistent or recurrent disease. The main cause of morbidity and mortality is due to hypercalcemia complications [34] and less frequently to metastasis [46].

4. Conclusion

The presented case emphasizes the requirement of high clinical suspicion of parathyroid carcinoma in the presence of very high level of iPTH, marked hypercalcemia, and overt skeletal and renal involvement. The existence of any thyroid nodules should be approached and coexistence of other carcinomas should be considered. Although imaging studies assist in the localization, reliable distinction of parathyroid carcinoma from adenoma cannot be made. Radical surgery is the only effective and curative treatment and should consist of initial en bloc resection of the tumor with ipsilateral thyroidectomy and central neck dissection.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Acknowledgments

The authors thank the Department of Endocrinology and Metabolism and Pathology of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.

References

E. Shane, “Parathyroid carcinoma,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 2, pp. 485–493, 2001.

F. Cetani, E. Pardi, and C. Marcocci, “Update on parathyroid carcinoma,” Journal of Endocrinological Investigation, vol. 39, no. 6, pp. 595–606, 2016.

E. Kebebew, “Parathyroid carcinoma,” Current Treatment Options in Oncology, vol. 2, no. 4, pp. 347–354, 2001.

J. M. Sharretts and W. F. Simonds, “Clinical and molecular genetics of parathyroid neoplasms,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 24, no. 3, pp. 491–502, 2010.

L. Wang, D. Han, W. Chen et al., “Non-functional parathyroid carcinoma: a case report and review of the literature,” Cancer Biology & Therapy, vol. 16, no. 11, pp. 1569–1576, 2015.

B. J. Wilkins and J. S. Lewis Jr., “Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery,” Head and Neck Pathology, vol. 3, no. 2, pp. 140–149, 2009.

S. Guth, U. Theune, J. Aberle, A. Galach, and C. M. Bamberger, “Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination,” European Journal of Clinical Investigation, vol. 39, no. 8, pp. 699–706, 2009.

L. Dal Maso, C. Panato, S. Franceschi et al., “The impact of overdiagnosis on thyroid cancer epidemic in Italy, 1998–2012,” European journal of cancer, vol. 94, pp. 6–15, 2018.

L. Davies, L. G. T. Morris, M. Haymart et al., “American Association of Clinical Edocrinologists and American College of Endocrinology Disease State Clinical Review: the increasing incidence of thyroid cancer,” Endocrine Practice, vol. 21, no. 6, pp. 686–696, 2015.

M. Mileva, B. Stoilovska, A. Jovanovska et al., “Thyroid cancer detection rate and associated risk factors in patients with thyroid nodules classified as bethesda category III,” Radiology and Oncology, vol. 52, no. 4, pp. 370–376, 2018.

H. Lim, S. S. Devesa, J. A. Sosa, D. Check, and C. M. Kitahara, “Trends in thyroid cancer incidence and mortality in the United States, 1974–2013,” JAMA, vol. 317, no. 13, pp. 1338–1348, 2017.

F. Rahmat, A. Kumar Marutha Muthu, N. S. R. Gopal, S. Jo Han, and A. S. Yahaya, “Papillary thyroid carcinoma as a lateral neck cyst: a cystic metastatic node versus an ectopic thyroid tissue,” Case Reports in Endocrinology, vol. 2018, Article ID 5198297, 3 pages, 2018.

S. Suzuki, T. I. Bogdanova, V. A. Saenko et al., “Histopathological analysis of papillary thyroid carcinoma detected during ultrasound screening examinations in Fukushima,” Cancer Science, vol. 110, no. 2, pp. 817–827, 2019.

S. Tseleni-Balafouta, H. Gakiopoulou, N. Kavantzas, G. Agrogiannis, N. Givalos, and E. Patsouris, “Parathyroid proliferations,” Cancer, vol. 111, no. 2, pp. 130–136, 2007.

H. Mazeh, D. Prus, and H. R. Freund, “Incidental non-functional parathyroid carcinoma identified during thyroidectomy,” Israel Medical Association Journal, vol. 10, no. 8-9, p. 659, 2008.

M. Goldfarb, P. O’Neal, J. Shih, P. Hartzband, J. Connolly, and P.-O. Hasselgren, “Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidism,” Endocrine Practice, vol. 15, no. 5, pp. 463–468, 2009.

P.-Y. Marcy, J. Thariat, A. Sudaka, and G. Poissonnet, “Synchronous parathyroid and papillary thyroid carcinomas,” Thyroid, vol. 19, no. 10, pp. 1131–1133, 2009.

L. Chaychi, K. Belbruno, A. Golding, and V. Memoli, “Unusual manifestation of parathyroid carcinoma in the setting of papillary thyroid cancer,” Endocrine Practice, vol. 16, no. 4, pp. 664–668, 2010.

H. A. Amoodi, F. M. Makki, S. Mark Taylor, M. J. Bullock, R. D. Hart, and J. R. Trites, “Synchronous thyroid/parathyroid carcinomas,” Journal of Otolaryngology—Head & Neck Surgery, vol. 39, no. 5, pp. E42–E47, 201.

S. Basceken, V. Genc, S. Ersoz, Y. Sevim, S. Celik, and I. Bayram, “Is local resection sufficient for parathyroid carcinoma?” Clinics, vol. 70, no. 4, pp. 247–249, 2015.

M. Zakerkish, E. Rajaei, M. Dargahi, and M. Bahadoram, “A rare constellation of Hürthle cell thyroid carcinoma and parathyroid carcinoma,” Journal of Clinical and Diagnostic Research, vol. 9, no. 12, 2015.

H. Savli, A. Sevinc, R. Sari, S. Ozen, S. Buyukberber, and E. Ertas, “Occult parathyroid carcinoma in a patient with papillary thyroid carcinoma and Hashimoto’s thyroiditis,” Journal of Endocrinological Investigation, vol. 24, no. 1, pp. 42–44, 2001.

C.-O. Baek, K. H. Kim, and S. K. Song, “Synchronous parathyroid carcinoma and papillary thyroid carcinoma in a patient with long-standing schizophrenia,” The Korean Journal of Internal Medicine, vol. 32, no. 6, pp. 1104–1107, 2017.

G. Schoretsanitis, J. Melissas, M. Kafousi, N. Karkavitsas, and D. D. Tsiftsis, “Synchronous parathyroid and papillary thyroid carcinoma: a case report,” American Journal of Otolaryngology, vol. 23, no. 6, pp. 382–385, 2002.

S.-D. Lin, S.-T. Tu, S.-R. Hsu, J. H.-M. Chang, K.-T. Yang, and L.-H. Yang, “Synchronous parathyroid and papillary thyroid carcinoma,” Journal of the Chinese Medical Association, vol. 68, no. 2, pp. 87–91, 2005.

T. J. Christmas, C. R. Chapple, J. G. Noble, E. J. G. Milroy, and A. G. A. Cowie, “Hyperparathyroidism after neck irradiation,” British Journal of Surgery, vol. 75, no. 9, pp. 873-874, 1988.

G. Bednarek-Tupikowska, T. Tolloczko, W. Tupikowski et al., “Coexistence of parathyroid carcinoma and non-medullary carcinoma of the thyroid,” Medical Science Monitor, vol. 7, no. 3, pp. 448–456, 2001.

M. Kern, G. Lee, P. Robbins, M. Bynevelt, and P. Watson, “Intracranial metastatic parathyroid carcinoma,” Journal of Neurosurgery, vol. 101, no. 6, pp. 1065–1069, 2004.

F. Kuzu, A. Cinkaya, M. Ekici, H. Kodaz, and A. Deger, “Synchronous parathyroid carcinoma and multifocal papillary thyroid carcinoma: a case report,” Eurasian Journal of Medicine and Oncology, vol. 1, no. 1, pp. 49–52, 2017.

C. Song, J. Wang, X. Cai, and L. Gao, “Synchronous parathyroid carcinoma and papillary thyroid carcinoma : a case study and review of literature,” International Journal of Clinical and Experimental Pathology, vol. 9, no. 1, pp. 302–309, 2016.

A. Campennì, S. Giovinazzo, S. A. Pignata et al., “Association of parathyroid carcinoma and thyroid disorders: a clinical review,” Endocrine, vol. 56, no. 1, pp. 19–26, 2017.

http://seer.cancer.gov/statfacts/html/thyro.html.

C. E. Quinn, J. Healy, A. H. Lebastchi et al., “Modern experience with aggressive parathyroid tumors in a high-volume New England referral center,” Journal of the American College of Surgeons, vol. 220, no. 6, pp. 1054–1062, 2015.

T. Obara and Y. Fujimoto, “Diagnosis and treatment of patients with parathyroid carcinoma: an update and review,” World Journal of Surgery, vol. 15, no. 6, pp. 738–744, 1991.

E. Shane and J. P. Bilezikian, “Parathyroid carcinoma: a review of 62 patients,” Endocrine Reviews, vol. 3, no. 2, pp. 218–226, 1982.

Y. Kushchayeva, Q.-Y. Duh, E. Kebebew, A. D’Avanzo, and O. H. Clark, “Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with hurthle cell or follicular thyroid cancer,” The American Journal of Surgery, vol. 195, no. 4, pp. 457–462, 2008.

S. K. G. Grebe and I. D. Hay, “Follicular thyroid cancer,” Endocrinology and Metabolism Clinics of North America, vol. 24, no. 4, pp. 761–801, 1995.

S. Kurita, S. Mihashi, M. Hirano, T. Nakashima, and A. Tanimura, “Hyperfunctioning parathyroid carcinoma combined with papillary carcinoma of the thyroid gland—report of a case (author’s transl),” Nihon Gan Chiryo Gakkai Shi, vol. 14, no. 7, pp. 1127–1135, 1979.

J. B. Koea and J. H. F. Shaw, “Parathyroid cancer: biology and management,” Surgical Oncology, vol. 8, no. 3, pp. 155–165, 1999.

K. Dikmen, H. Bostanci, H. Gobut et al., “Nonfunctional double parathyroid carcinoma with incidental thyroid micropapillary carcinoma: a rare case,” The Pan African Medical Journal, vol. 27, p. 241, 2017.

G. G. Fernandez-Ranvier, E. Khanafshar, K. Jensen et al., “Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis?” Cancer, vol. 110, no. 2, pp. 255–264, 2007.

A. Schantz and B. Castleman, “Parathyroid carcinom: a study of 70 cases,” Cancer, vol. 31, no. 3, pp. 600–605, 1973.

B. Givi and J. P. Shah, “Parathyroid carcinoma,” Clinical Oncology, vol. 22, no. 6, pp. 498–507, 2010.

A. Arnold, “Genetic basis of endocrine disease 5: molecular genetics of parathyroid gland neoplasia,” Journal of Clinical Endocrinology & Metabolism, vol. 77, no. 5, pp. 1108–1112, 1993.

T. M. Shattuck, S. Välimäki, T. Obara et al., “Somatic and germ-line mutations of theHRPT2Gene in sporadic parathyroid carcinoma,” New England Journal of Medicine, vol. 349, no. 18, pp. 1722–1729, 2003.

A. Campennì, R. M. Ruggeri, A. Sindoni et al., “Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism,” Journal of Bone and Mineral Metabolism, vol. 30, no. 3, pp. 367–372, 2012.